Forest Laboratories UK Ltd

Forest Laboratories UK Ltd Submits Marketing Authorisation Application for the First Dry Powder Inhalation Antibiotic for Cystic Fibrosis Patients

Older News

LONDON - Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest Laboratories Inc) announced that following the successful completion of its pan-European multi-centre phase III study (the Freedom Study), it has applied to the European Medicines Evaluation Agency (EMEA) to licence its new formulation dry powder colistimethate sodium for inhalation (Colobreathe(R)) for use by Cystic Fibrosis patients.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy